Companion Spine expanded its implant portfolio with the acquisition of Backbone, maker of the LISA® lumbar implant for stiffness augmentation. This acquisition allows Companion Spine to complete its line of treatment solutions for spine diseases, most notably lumbar stenosis and degenerative disc disease.
The LISA device is designed to reduce chronic pain related to degenerative diseases of the lumbar spine, preserving form, function and motion while balancing and restoring the patient’s freedom of movement.
LISA has been CE marked since 2018. Backbone conducted a clinical study on 137 patients in five centers in Europe to demonstrate its safety and efficacy, and to provide scientific support for its commercial development in lumbar degenerative disc disease.
Erick Cloix, CEO and co-founder of Companion Spine, said, “Our DIAM™ implant is oriented towards a lesser spine pain pathology, while the LISA implant provides a more solid support controlling both flexion and extension of the back. The complementary nature of these two products allows Companion Spine to offer a full range of therapeutic solutions, in response to the whole range of pathologies involving the spine, from lumbar stenosis to degenerative disc disease, and for each degree of severity.”
Companion Spine expanded its implant portfolio with the acquisition of Backbone, maker of the LISA® lumbar implant for stiffness augmentation. This acquisition allows Companion Spine to complete its line of treatment solutions for spine diseases, most notably lumbar stenosis and degenerative disc disease.
The LISA device is designed to reduce...
Companion Spine expanded its implant portfolio with the acquisition of Backbone, maker of the LISA® lumbar implant for stiffness augmentation. This acquisition allows Companion Spine to complete its line of treatment solutions for spine diseases, most notably lumbar stenosis and degenerative disc disease.
The LISA device is designed to reduce chronic pain related to degenerative diseases of the lumbar spine, preserving form, function and motion while balancing and restoring the patient’s freedom of movement.
LISA has been CE marked since 2018. Backbone conducted a clinical study on 137 patients in five centers in Europe to demonstrate its safety and efficacy, and to provide scientific support for its commercial development in lumbar degenerative disc disease.
Erick Cloix, CEO and co-founder of Companion Spine, said, “Our DIAM™ implant is oriented towards a lesser spine pain pathology, while the LISA implant provides a more solid support controlling both flexion and extension of the back. The complementary nature of these two products allows Companion Spine to offer a full range of therapeutic solutions, in response to the whole range of pathologies involving the spine, from lumbar stenosis to degenerative disc disease, and for each degree of severity.”
Copy to clipboard 
